What is BASDAI?
The Bath Ankylosing Spondylitis Disease Activity Index, commonly known as BASDAI, is one of the most widely used instruments for measuring disease activity in patients with ankylosing spondylitis (AS). Developed in 1994 by Garrett et al. at the Royal National Hospital for Rheumatic Diseases in Bath, England, BASDAI was created to provide a reliable, patient-reported outcome measure that could be used both in clinical trials and routine clinical practice.
Before BASDAI was introduced, there was no standardized method for assessing how active the disease was from the patient's perspective. Laboratory markers such as ESR and CRP often failed to correlate well with the subjective experience of AS symptoms. The development team recognized that a simple questionnaire, scored by patients themselves, could capture the multidimensional nature of the disease far more effectively than any single blood test. BASDAI consists of six questions covering the five major symptom domains of AS: fatigue, spinal pain, peripheral joint pain, enthesitis (tenderness), and morning stiffness (both severity and duration). It produces a score ranging from 0 to 10, with higher scores indicating greater disease activity. A score of 4 or above is widely accepted as the threshold indicating active disease that may require a change in treatment approach.
What is Ankylosing Spondylitis?
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints at the base of the spine. Over time, the inflammation can cause new bone formation in the spine, leading to sections of the spine fusing together in a fixed, immobile position. The name comes from the Greek words "ankylos" meaning stiffening or fusing of a joint, and "spondylos" meaning vertebra. AS belongs to a group of conditions called spondyloarthropathies, which share common features including spinal involvement and a strong genetic association with the HLA-B27 gene.
AS typically begins in late adolescence or early adulthood, most commonly between the ages of 17 and 45. It affects approximately 0.1% to 0.5% of the general population, though prevalence varies significantly across different ethnic groups and geographic regions. Historically, AS was thought to predominantly affect men, with ratios cited as high as 3:1 male to female. However, more recent research suggests the actual ratio may be closer to 2:1, with women often experiencing underdiagnosis due to different symptom presentations. Common symptoms include chronic lower back pain and stiffness that worsen with rest and improve with exercise, fatigue, peripheral joint pain, enthesitis (inflammation where tendons and ligaments attach to bone), and in some cases, extra-articular manifestations such as anterior uveitis (eye inflammation), inflammatory bowel disease, and psoriasis.
The 6 BASDAI Questions Explained
Each of the six BASDAI questions targets a specific aspect of ankylosing spondylitis symptoms. Understanding what each question measures helps patients provide more accurate responses, leading to a more reliable overall score.
Question 1 (Fatigue): This question assesses the overall level of tiredness and exhaustion. Fatigue is one of the most debilitating yet often overlooked symptoms of AS. It results from chronic inflammation, disrupted sleep due to pain, and the body's constant immune response. Patients rate their fatigue from 0 (none) to 10 (very severe).
Question 2 (Spinal Pain): This measures the overall level of pain in the neck, back, or hips, which are the primary sites affected by AS. This inflammatory back pain tends to be worse at night and in the morning, improving with physical activity rather than rest.
Question 3 (Peripheral Joint Pain/Swelling): This captures pain and swelling in joints other than the spine, such as knees, ankles, shoulders, and wrists. Approximately 30-50% of AS patients experience peripheral arthritis at some point during their disease.
Question 4 (Enthesitis): This assesses tenderness at entheses, which are the points where tendons and ligaments insert into bone. Common sites include the heel (Achilles tendon), the bottom of the foot (plantar fascia), and the ribcage.
Questions 5 and 6 (Morning Stiffness): These two questions work together to measure morning stiffness, a hallmark symptom of AS. Question 5 assesses the severity of morning stiffness, while Question 6 measures its duration. These two scores are averaged together in the final BASDAI calculation because they represent different dimensions of the same symptom.
How to Calculate Your BASDAI Score
The BASDAI score is calculated using a specific formula that weighs all six questions equally while treating the two morning stiffness questions as a single combined measure. The calculation process is straightforward and can be done by hand or using this calculator.
First, answer each of the six questions on a scale of 0 to 10. Next, add together the scores for Questions 5 and 6 and divide by 2 to get the average morning stiffness score. Then, add the scores for Questions 1 through 4 to this average morning stiffness score. Finally, divide the total by 5 to get your BASDAI score.
Example calculation: Suppose a patient reports: Q1 (fatigue) = 6, Q2 (spinal pain) = 7, Q3 (peripheral pain) = 3, Q4 (enthesitis) = 5, Q5 (morning stiffness severity) = 8, Q6 (morning stiffness duration) = 6. First, calculate the morning stiffness mean: (8 + 6) / 2 = 7. Then add all terms: 6 + 7 + 3 + 5 + 7 = 28. Finally, divide by 5: 28 / 5 = 5.6. This BASDAI score of 5.6 indicates moderate disease activity that may warrant a discussion about treatment adjustment.
Interpreting Your BASDAI Score
The BASDAI score ranges from 0 to 10, with clearly defined clinical thresholds that guide treatment decisions. Understanding what your score means can help you have more productive conversations with your rheumatologist about your care plan.
| Score Range | Disease Activity | Clinical Meaning |
|---|---|---|
| 0 to < 4 | Low disease activity | Disease is generally well controlled. Current treatment regimen appears effective. Continue monitoring. |
| 4 to 6 | Moderate disease activity | Disease may not be adequately controlled. Treatment adjustment should be discussed with your physician. |
| > 6 | High disease activity | Significant disease burden present. A change in treatment strategy is likely needed. Consider biologic therapy if not already started. |
A score of 4 or above is commonly used as the cutoff point for eligibility for biologic therapy, particularly anti-TNF agents, in many national treatment guidelines. However, the BASDAI score should never be used in isolation. Clinicians consider it alongside other factors including CRP levels, imaging findings, physical examination, and the patient's overall clinical picture when making treatment decisions. It is also important to track BASDAI scores over time; a sustained reduction of 2 or more points, or a decrease of 50% or more, is generally considered a clinically significant improvement.
BASDAI in Clinical Practice
In clinical practice, BASDAI serves as a cornerstone tool for monitoring disease activity and guiding therapeutic decisions in ankylosing spondylitis management. Rheumatologists typically ask patients to complete the BASDAI questionnaire at each clinic visit, which usually occurs every 3 to 6 months for patients with active disease and annually for those in remission or with well-controlled disease.
The BASDAI is particularly valuable when assessing response to treatment. When a new therapy is started, BASDAI is measured at baseline and then at regular intervals (often at 12 weeks) to evaluate whether the treatment is effective. Many national health systems and insurance guidelines use BASDAI as part of the criteria for initiating and continuing biologic therapies. For example, the British Society for Rheumatology recommends that patients have a BASDAI of 4 or more on two occasions at least 12 weeks apart, despite adequate trials of at least two NSAIDs, before being eligible for anti-TNF therapy. The BASDAI is also used extensively in clinical research as a primary or secondary endpoint in trials of new AS treatments. Its simplicity, reliability, and sensitivity to change make it an ideal tool for comparing treatment efficacy across different studies and patient populations.
Treatment Options for AS
Treatment for ankylosing spondylitis aims to reduce pain and stiffness, maintain spinal flexibility and posture, prevent structural damage, and optimize quality of life. The approach is typically stepwise, starting with conservative measures and escalating to more targeted therapies as needed based on disease activity scores like BASDAI.
NSAIDs: Non-steroidal anti-inflammatory drugs remain the first-line pharmacological treatment for AS. Medications such as naproxen, diclofenac, and indomethacin can effectively reduce pain and stiffness. Continuous NSAID use has been shown to slow radiographic progression in some studies. However, long-term use carries risks of gastrointestinal and cardiovascular side effects.
Biologic therapies: TNF inhibitors such as adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol have revolutionized the treatment of AS. They are recommended for patients who maintain a BASDAI of 4 or more despite adequate NSAID therapy. More recently, IL-17 inhibitors (secukinumab, ixekizumab) and JAK inhibitors (tofacitinib, upadacitinib) have expanded the treatment options available.
Exercise and physiotherapy: Regular exercise is considered an essential component of AS management. Structured exercise programs focusing on stretching, strengthening, and aerobic fitness can significantly improve mobility, reduce pain, and enhance quality of life. Swimming and water-based exercises are particularly beneficial due to the low-impact nature and warmth of the water.
Limitations of BASDAI
While BASDAI remains one of the most commonly used instruments in AS assessment, it is important to understand its limitations. The most significant limitation is that BASDAI is entirely subjective, relying solely on patient self-report without incorporating any objective measures of inflammation or structural damage. Two patients with identical levels of inflammation may report very different BASDAI scores based on their pain tolerance, psychological state, and interpretation of the questions.
Another limitation is that BASDAI does not distinguish between disease activity caused by active inflammation and symptoms resulting from structural damage that has already occurred. A patient with significant spinal fusion may report high pain and stiffness scores even though there is no active inflammation present, potentially leading to inappropriate escalation of anti-inflammatory therapy. BASDAI also does not capture extra-articular manifestations such as uveitis, inflammatory bowel disease, or psoriasis, which are important components of the overall disease burden.
To address some of these limitations, the Ankylosing Spondylitis Disease Activity Score (ASDAS) was developed as an alternative measure. ASDAS combines patient-reported outcomes (including three BASDAI questions) with an objective inflammatory marker (CRP or ESR), providing a composite score that better reflects the underlying inflammatory process. Many rheumatologists now use ASDAS alongside or instead of BASDAI for clinical decision-making, particularly when considering biologic therapy initiation.
Living with Ankylosing Spondylitis
Living well with ankylosing spondylitis requires a comprehensive approach that goes beyond medication alone. Regular physical activity is perhaps the single most important self-management strategy. Daily stretching exercises help maintain spinal flexibility and prevent the progressive stiffness that characterizes AS. A combination of range-of-motion exercises, strengthening exercises for core and back muscles, and cardiovascular fitness activities provides the best outcomes.
Posture awareness is critical for people with AS. Being mindful of maintaining good posture throughout the day, including at work and during sleep, can help prevent the forward-stooping posture (kyphosis) that can develop as the disease progresses. Sleeping on a firm mattress with a thin pillow, or no pillow, and sleeping on your back when possible helps maintain spinal alignment. Ergonomic adjustments at the workplace, such as using a standing desk or an ergonomic chair, can also make a significant difference.
Heat therapy, including warm baths, hot packs, and heated pools, can help relieve stiffness and pain, particularly in the morning. Some patients also find cold therapy helpful for acute flares of peripheral joint inflammation. Joining a support group, whether in person or online, can provide emotional support, practical tips, and a sense of community with others who understand the daily challenges of living with AS. Organizations such as the Spondylitis Association of America and the National Ankylosing Spondylitis Society offer valuable resources and community connections.
Frequently Asked Questions
How often should I calculate my BASDAI score?
It is recommended to calculate your BASDAI score at each rheumatology appointment, typically every 3 to 6 months for active disease. You can also track it at home weekly or monthly to identify patterns and triggers. Keeping a log of your scores over time gives your doctor valuable information for adjusting treatment plans.
Can BASDAI diagnose ankylosing spondylitis?
No, BASDAI is not a diagnostic tool. It measures disease activity in people who have already been diagnosed with ankylosing spondylitis. Diagnosis of AS requires a combination of clinical history, physical examination, imaging (X-rays or MRI of the sacroiliac joints), and sometimes blood tests including HLA-B27 testing.
What is the difference between BASDAI and ASDAS?
BASDAI is entirely based on patient self-report, while ASDAS (Ankylosing Spondylitis Disease Activity Score) combines patient-reported symptoms with an objective inflammatory marker (CRP or ESR). ASDAS is considered by many experts to provide a more comprehensive assessment of disease activity. However, BASDAI remains widely used due to its simplicity and the fact that it does not require a blood test.
What does a BASDAI score of 4 mean for my treatment?
A BASDAI score of 4 or higher is widely used as the threshold for considering biologic therapy such as TNF inhibitors. If your score is consistently at or above 4 despite adequate trial of at least two NSAIDs, your rheumatologist may discuss starting biologic treatment. However, treatment decisions also consider other clinical factors, imaging results, and inflammatory markers.
Can my BASDAI score change day to day?
Yes, BASDAI scores can fluctuate from day to day based on disease flares, activity levels, sleep quality, stress, and other factors. This is why BASDAI asks patients to rate their symptoms over the past week. For clinical decisions, sustained changes over multiple assessments are more meaningful than any single measurement.
Is a BASDAI score of 0 possible?
A BASDAI score of 0 means the patient reports no fatigue, no spinal pain, no peripheral joint pain, no enthesitis, and no morning stiffness. While uncommon in someone with an AS diagnosis, it can occur in patients who are in remission or whose disease is very well controlled by treatment. A very low BASDAI does not mean the disease is cured, and ongoing monitoring remains important.
Should I complete BASDAI before or after taking my medication?
For the most accurate clinical picture, BASDAI should be completed consistently at the same time relative to your medication schedule. Most guidelines suggest completing it before taking your morning medications, as this best reflects your underlying disease activity. Always discuss timing with your rheumatologist to ensure consistent and comparable results across visits.